{"id":12690,"date":"2025-01-27T14:27:01","date_gmt":"2025-01-27T19:27:01","guid":{"rendered":"https:\/\/transfusionontario.org\/?p=12690"},"modified":"2025-01-27T15:11:41","modified_gmt":"2025-01-27T20:11:41","slug":"antiphospholipid-syndrome-catastrophic-igum","status":"publish","type":"post","link":"https:\/\/transfusionontario.org\/en\/antiphospholipid-syndrome-catastrophic-igum\/","title":{"rendered":"Antiphospholipid syndrome &#8211; catastrophic"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">(See separate entry for <a href=\"https:\/\/transfusionontario.org\/en\/antiphospholipid-syndrome-other-than-catastrophic-igum\">Antiphospholipid Syndrome<\/a>)<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-color has-link-color has-medium-font-size wp-elements-8c2c274f80c427244f898c8cc142e57d\" style=\"color:#477d6c\"><strong>Recommended Indications in which IG can be used<\/strong><\/h2>\n\n\n\n<h3 class=\"wp-block-heading has-black-color has-text-color has-background has-link-color has-small-font-size wp-elements-e12175a98a8cfa79a026b7a7dd5a4250\" style=\"background-color:#a5cbbf\"><strong>Order Number: R1-ASC<\/strong><span style=\"font-size: medium; font-weight: 400; white-space-collapse: collapse;\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table is-style-regular\"><table><tbody><tr><td><strong>Recommendations<\/strong><\/td><td>IVIG is recommended for catastrophic antiphospholipid syndrome, characterized by widespread small vessel thrombosis leading to multiorgan failure.<br>&nbsp;<br><strong>Qualifying Criteria<\/strong><br>All of the following criteria must be met:<br><ul><li>Evidence of rapidly evolving thrombosis involving two or more organs.<\/li><li>Unequivocal laboratory evidence of antiphospholipid antibodies (lupus anticoagulant and\/or anticardiolipin antibodies and\/or beta 2 glycoprotein I antibodies). <\/li><li>Other causes of thrombotic microangiopathy are considered less likely. <\/li><\/ul><\/td><\/tr><tr><td><strong>Dose\/Frequency of Administration<\/strong><\/td><td>2 g\/kg adjusted body weight divided over 2 to 5 days. A single treatment is usually sufficient.<br><br>The potential prothrombotic effect of IVIG should be considered in this indication.<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Recommended Indications in which IG can be used<\/p>\n<p>Order Number: R1-ASC<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"_tec_requires_first_save":true,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","footnotes":""},"categories":[399],"tags":[],"class_list":["post-12690","post","type-post","status-publish","format-standard","hentry","category-rheumatology-indications"],"acf":[],"_links":{"self":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/posts\/12690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/comments?post=12690"}],"version-history":[{"count":0,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/posts\/12690\/revisions"}],"wp:attachment":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/media?parent=12690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/categories?post=12690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/tags?post=12690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}